Spots Global Cancer Trial Database for nonsmall cell lung cancer
Every month we try and update this database with for nonsmall cell lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | NCT02972333 | EGFR-TKI Resist... Nonsmall Cell L... AZD9291 Brain Metastase... | AZD9291 80mg or... Radiation thera... | 18 Years - | Shandong Cancer Hospital and Institute | |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | NCT05275374 | Cancer BRAF V600 Mutat... Melanoma Colorectal Canc... Thyroid Cancer Nonsmall Cell L... | XP-102 Trametinib | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC | NCT03769805 | Nonsmall Cell L... | Anlotinib | 18 Years - 74 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | NCT02358473 | Non-Small Cell ... | mogamulizumab Docetaxel | 18 Years - | Kyowa Kirin, Inc. | |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | NCT02705339 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Rociletinib Biopsy Blood draw | 18 Years - | Washington University School of Medicine | |
| Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) | NCT01312337 | Nonsmall Cell L... | salvage iressa | 18 Years - | Samsung Medical Center | |
| A Mobile Supportive Care App for Patients With Metastatic Lung Cancer | NCT03512015 | Nonsmall Cell L... Small Cell Lung... | The Lung Cancer... Standard care | 18 Years - | Bocconi University | |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | NCT04396340 | Ovarian Cancer Nonsmall Cell L... | XMT-1592 | 18 Years - 95 Years | Mersana Therapeutics | |
| Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis | NCT01301560 | Nonsmall Cell L... | Radiosurgery Observation | 18 Years - | Samsung Medical Center | |
| THIO Sequenced With Cemiplimab in Advanced NSCLC | NCT05208944 | Carcinoma, Non-... | 6-Thio-2'-Deoxy... Cemiplimab | 18 Years - | Maia Biotechnology | |
| Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer | NCT03450330 | Nonsmall Cell L... | AZD4205 | 18 Years - | Dizal Pharmaceuticals | |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | NCT05863052 | Immune Checkpoi... Metastatic Soli... Nonsmall Cell L... Melanoma Renal Cell Carc... Gastrointestina... Squamous Cell C... | Immunotherapy | 18 Years - 99 Years | University of Oklahoma | |
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | NCT02972333 | EGFR-TKI Resist... Nonsmall Cell L... AZD9291 Brain Metastase... | AZD9291 80mg or... Radiation thera... | 18 Years - | Shandong Cancer Hospital and Institute | |
| SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer | NCT02562027 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | European Organi... European Organi... Modified Medica... EQ-5D Center for Epid... Medical Outcome... | 18 Years - | Washington University School of Medicine | |
| Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC | NCT03044626 | Carcinoma，Non-S... Metastatic Lung... Nonsmall Cell L... Lung Adenocarci... Large Cell Lung... | Radiotherapy Nivolumab | 18 Years - | AIO-Studien-gGmbH | |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | NCT04396340 | Ovarian Cancer Nonsmall Cell L... | XMT-1592 | 18 Years - 95 Years | Mersana Therapeutics | |
| Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | NCT03050411 | Nonsmall Cell L... | Apatinib Mesyla... EGFR-TKIs (Erlo... | 18 Years - 75 Years | Peking University Third Hospital | |
| A Study of [14C]GB491 in Male Healthy Subjects | NCT05860582 | Breast Cancer Nonsmall Cell L... | [14C]GB491 | 18 Years - 50 Years | Genor Biopharma Co., Ltd. | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | NCT06147570 | Nonsmall Cell L... | HS-10365 capsul... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | NCT02716038 | Carcinoma, Non-... | MPDL3280A Carboplatin Nab-paclitaxel | 18 Years - | Columbia University | |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) | NCT02419170 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Standard of car... Apheresis Cyclophosphamid... Personalized ma... | 18 Years - | Washington University School of Medicine | |
| Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression | NCT02431169 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | 18 Years - | Washington University School of Medicine | ||
| Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer | NCT00049998 | Non-Small-Cell ... | topotecan | 18 Years - | GlaxoSmithKline | |
| Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients | NCT02010047 | Nonsmall Cell L... | ALK qPCR assay | 19 Years - | British Columbia Cancer Agency | |
| Effects of Acupuncture Stimulation on Systemic Inflammation | NCT02951611 | Nonsmall Cell L... | Acupuncture sti... Sham stimulatio... | 18 Years - 75 Years | RenJi Hospital | |
| IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer | NCT03258671 | Non-Small Cell ... Nonsmall Cell L... Carcinoma, Non-... | EGFR-TK Inhibit... Intensity Modul... | 18 Years - 80 Years | Guizhou Medical University | |
| Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy | NCT00745797 | Brain Metastase... | Radiotherapy | 18 Years - 75 Years | Chinese Society of Lung Cancer | |
| CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology | NCT03940846 | Nonsmall Cell L... | Virtual biopsy | - | Maastricht University | |
| Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | NCT05873439 | Nonsmall Cell L... Nonsmall Cell L... Nonsmall Cell L... Unresectable No... | Genomically Gui... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | NCT05873439 | Nonsmall Cell L... Nonsmall Cell L... Nonsmall Cell L... Unresectable No... | Genomically Gui... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | NCT02705339 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Rociletinib Biopsy Blood draw | 18 Years - | Washington University School of Medicine | |
| Study of Lorlatinib in ROS1 Rearranged NSCLC | NCT03612154 | Nonsmall Cell L... | Lorlatinib | 18 Years - | National Cancer Center, Korea | |
| Study of Lorlatinib in ROS1 Rearranged NSCLC | NCT03612154 | Nonsmall Cell L... | Lorlatinib | 18 Years - | National Cancer Center, Korea | |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) | NCT02419170 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Standard of car... Apheresis Cyclophosphamid... Personalized ma... | 18 Years - | Washington University School of Medicine | |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer | NCT01999673 | Non-Small-Cell ... Non-Small-Cell ... Non-Small-Cell ... Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | bavituximab Docetaxel Placebo (for ba... | 18 Years - | Peregrine Pharmaceuticals | |
| Genetic Predictors of Benefit to Pembrolizumab | NCT02710396 | Carcinoma, Non-... | Pembrolizumab Carboplatin Nab-paclitaxel Pemetrexed | 18 Years - | Columbia University | |
| Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients | NCT01192230 | Carcinoma, Non-... | Endostatins Docetaxel | 18 Years - 80 Years | Fudan University | |
| Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy | NCT00864331 | Non Small Cell ... | radiation Chemotherapy an... Chemotherapy Palliative radi... | 18 Years - | International Atomic Energy Agency | |
| EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | NCT03002844 | Nonsmall Cell L... EGFR Gene Mutat... | EGFR-TK Inhibit... EGFR-TKI EGFR-TKI and Ch... | 18 Years - 70 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression | NCT02431169 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | 18 Years - | Washington University School of Medicine | ||
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | NCT02537561 | Solid Tumors Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Cisplatin Gemcitabine Talazoparib | 18 Years - | Washington University School of Medicine | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| Metabolic and Microbial Profiling of Lung Cancer | NCT03998189 | Nonsmall Cell L... Nonsmall Cell L... | Breath Collecti... Saliva Collecti... Blood Collectio... Urine Collectio... Tumor Collectio... Medical History... | 18 Years - | Wake Forest University Health Sciences | |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | NCT02537561 | Solid Tumors Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Cisplatin Gemcitabine Talazoparib | 18 Years - | Washington University School of Medicine | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | NCT02981108 | Nonsmall Cell L... | HS-10296 | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| The Tracking Molecular Evolution for NSCLC (T-MENC) Study | NCT03838588 | Lung Neoplasms Lung Cancer Nonsmall Cell L... Adenocarcinoma ... | 18 Years - 80 Years | Geneplus-Beijing Co. Ltd. | ||
| MYLUNG Consortium Study Protocol 2 | NCT05644808 | Carcinoma, Non-... | 18 Years - | US Oncology Research | ||
| Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) | NCT01312337 | Nonsmall Cell L... | salvage iressa | 18 Years - | Samsung Medical Center | |
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | NCT02299141 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Nintedanib | 18 Years - | Washington University School of Medicine | |
| Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02342353 | Non-Small Cell ... Nonsmall Cell L... Carcinoma, Non-... | Pacritinib Erlotinib | 18 Years - | Washington University School of Medicine | |
| Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer | NCT02994576 | Nonsmall Cell L... | Atezolizumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | NCT06147570 | Nonsmall Cell L... | HS-10365 capsul... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Patient-centered, Optimal Integration of Survivorship and Palliative Care | NCT04900935 | Stage IV Non-sm... Targeted Therap... Nonsmall Cell L... Carcinoma, Non-... ALK-positive No... EGFR Positive N... Palliative Care Survivorship | POISE | 18 Years - | Massachusetts General Hospital | |
| CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology | NCT03940846 | Nonsmall Cell L... | Virtual biopsy | - | Maastricht University | |
| EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | NCT03002844 | Nonsmall Cell L... EGFR Gene Mutat... | EGFR-TK Inhibit... EGFR-TKI EGFR-TKI and Ch... | 18 Years - 70 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | NCT06147570 | Nonsmall Cell L... | HS-10365 capsul... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Genetic Predictors of Benefit to Pembrolizumab | NCT02710396 | Carcinoma, Non-... | Pembrolizumab Carboplatin Nab-paclitaxel Pemetrexed | 18 Years - | Columbia University | |
| THIO Sequenced With Cemiplimab in Advanced NSCLC | NCT05208944 | Carcinoma, Non-... | 6-Thio-2'-Deoxy... Cemiplimab | 18 Years - | Maia Biotechnology | |
| Skeletal Muscle Atrophy and Dysfunction in Human Cancer | NCT02949076 | Nonsmall Cell L... | Exercise | 50 Years - 75 Years | University of Vermont | |
| Patient-centered, Optimal Integration of Survivorship and Palliative Care | NCT04900935 | Stage IV Non-sm... Targeted Therap... Nonsmall Cell L... Carcinoma, Non-... ALK-positive No... EGFR Positive N... Palliative Care Survivorship | POISE | 18 Years - | Massachusetts General Hospital | |
| Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC | NCT03769805 | Nonsmall Cell L... | Anlotinib | 18 Years - 74 Years | The First Affiliated Hospital with Nanjing Medical University | |
| X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | NCT03753685 | Nonsmall Cell L... Brain Metastase... | X-396(Ensartini... | 18 Years - | Fudan University | |
| Metabolic and Microbial Profiling of Lung Cancer | NCT03998189 | Nonsmall Cell L... Nonsmall Cell L... | Breath Collecti... Saliva Collecti... Blood Collectio... Urine Collectio... Tumor Collectio... Medical History... | 18 Years - | Wake Forest University Health Sciences | |
| Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | NCT02963610 | Relapsed or Ref... Nonsmall Cell L... | Lenalidomide Pembrolizumab | 18 Years - | Fox Chase Cancer Center | |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | NCT02716038 | Carcinoma, Non-... | MPDL3280A Carboplatin Nab-paclitaxel | 18 Years - | Columbia University | |
| MYLUNG Consortium Part 3: Observational Study | NCT05885698 | Carcinoma, Non-... | 18 Years - | US Oncology Research | ||
| A Biomarker Screening Protocol for Participants With Solid Tumors | NCT05891197 | Triple Negative... Nonsmall Cell L... | 18 Years - 99 Years | Lyell Immunopharma, Inc. | ||
| Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT03088540 | Carcinoma，Non-S... Lung Carcinomas... Non-small-cell ... Nonsmall Cell L... | Pemetrexed Paclitaxel Gemcitabine Cisplatin Carboplatin cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | NCT04984811 | Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Non Small Cell ... | efineptakin alf... Atezolizumab | 18 Years - | NeoImmuneTech | |
| X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | NCT03753685 | Nonsmall Cell L... Brain Metastase... | X-396(Ensartini... | 18 Years - | Fudan University | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| Study of Nivolumab for Advanced Cancers in India | NCT03444766 | Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms | Nivolumab | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
